Skip to main content
. Author manuscript; available in PMC: 2011 Jun 8.
Published in final edited form as: Mol Cancer Res. 2010 Jun 8;8(6):809–820. doi: 10.1158/1541-7786.MCR-09-0460

Figure 1.

Figure 1

A, GP and GR epithelial tumor cells are equally responsive to gefitinib. Equal numbers of GP and GR epithelial tumor cells seeded in 96-well plates were treated in quadruplicates with increasing concentrations of gefitinib (0, 0.1, 1, 5, 10 and 20 µM) for 5 days. End point cell viability was measured using the MTS assay and the data are represented as a percentage of the untreated sample. B, Same as in A, except cells from 60mm dishes were lysed and analyzed by immunoblot for pEGFR, EGFR, pMAPK, and β-actin. C, hEMP-1 is expressed in the GR CAFs. Quantitative RT-PCR analysis of hEMP-1 mRNA comparing GP to GR in the tumor tissue, epithelial tumor cells, and CAFs. Data are normalized to GAPDH and presented as fold induction of GP tumor tissue. D, FISH analysis of purified GP and GR CAFs with CEP Y (DYZ1) probe (green fluorescent signal) depicting human nuclei (white arrow) and murine nuclei (red arrow). Nuclear counter staining with DAPI (blue).